Drug Profile
SBT 300
Alternative Names: SBT-300Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Singh Biotechnology
- Class Antibodies; Antineoplastics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Actinic keratosis; Skin cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Actinic keratosis in USA (Topical)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Skin-cancer in USA (Topical)
- 23 Oct 2017 Preclinical trials in Actinic keratosis in USA before October 2017 (Topical) (Singh Biotechnology pipeline, October 2017)